View ValuationEXACT Therapeutics 将来の成長Future 基準チェック /06現在、 EXACT Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Apr 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.8m (US$9.64m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr72m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Revenue is less than US$1m (kr59k revenue, or US$6.3k). Market cap is less than US$10m (kr89.8m market cap, or US$9.64m).お知らせ • Feb 13EXACT Therapeutics AS, Annual General Meeting, Jun 12, 2026EXACT Therapeutics AS, Annual General Meeting, Jun 12, 2026.お知らせ • Feb 12+ 1 more updateEXACT Therapeutics AS to Report First Half, 2026 Results on Sep 03, 2026EXACT Therapeutics AS announced that they will report first half, 2026 results on Sep 03, 2026New Risk • Jul 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr82m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr174.6m market cap, or US$17.2m).お知らせ • Jun 24EXACT Therapeutics Announces First Patient Dosed in Phase 2 Trial in Patients with Locally Advanced Pancreatic CancerEXACT Therapeutics announced first patient dosed in its ENACT trial. The trial is a multi-centre, open-label Phase 2 clinical trial testing the safety and efficacy of Acoustic Cluster Therapy (ACT®) in combination with standard of care (modified FOLFIRINOX chemotherapy) in first line patients with borderline resectable or unresectable locally advanced pancreatic cancer. Dosing of the first patient in the Phase 2 trial follows the announcement of positive final efficacy and safety data in the Phase 1 trial in patients with liver metastases of colorectal origin. The Phase 2 trial will enroll up to 25 patients in the U.S., U.K. and Europe, and has the ClinicalTrials.gov Identification: NCT06850623.お知らせ • Jun 13Exact Therapeutics AS Approves Election of Following Nomination Committee CompositionEXACT Therapeutics AS at its AGM held on June 13, 2025 approved to elect the following Nomination Committee composition: Svein Kvåle (Chair), Birgitte Gangmark Villmo, Sir William Castell.お知らせ • May 20EXACT Therapeutics Announces Positive Final Results in Phase 1 ACTIVATE Trial in Liver Metastases from Colorectal CancerEXACT Therapeutics AS announced positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer. These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy (ACT®?) significantly enhances the local effect of chemotherapy; In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p. The final results affirm the previously reported positive ACTIVATE outcomes and indicate the significant added efficacy of ACT with chemotherapy compared with chemotherapy alone. Among patients who responded to chemotherapy, tumor shrinkage was significantly greater with ACT and chemotherapy compared to chemotherapy alone in the same individuals (29% vs. 7%, p<0.05).New Risk • Jan 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 97% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr221.4m market cap, or US$19.6m).お知らせ • Jan 29Cordance Medical and EXACT Therapeutics Announces Early Encouraging Data in Brain Cancer Mice ModelCordance Medical and EXACT Therapeutics announced initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics' proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and University Hospital North-Norway in Tromsø by Dr. Mathias Kranz. The combination of ACT® and the device can be used in a wide range of brain diseases to potentially access large regions of the brain. The combination can stimulate bioeffects including increasing the uptake of therapeutic agents and temporarily making the blood-brain barrier more permeable in these regions. The combination of ACT® and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals.お知らせ • Jan 28Exact Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice ModelEXACT Therapeutics and Cordance Medical announced initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics’ proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and the University Hospital of North-Norway in Tromsø by Dr. Mathias Kranz. The combination of ACT and the device may offer potential applications across a wide range of brain diseases, by enabling therapeutic access to large brain regions. The combined technologies can induce bioeffects, such as temporarily increasing blood-brain barrier permeability in targeted regions and increasing the uptake of therapeutic agents. ACT and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals.お知らせ • Jan 08EXACT Therapeutics AS, Annual General Meeting, Jun 13, 2025EXACT Therapeutics AS, Annual General Meeting, Jun 13, 2025.お知らせ • Jan 07+ 1 more updateEXACT Therapeutics AS to Report Fiscal Year 2025 Results on Apr 09, 2025EXACT Therapeutics AS announced that they will report fiscal year 2025 results on Apr 09, 2025お知らせ • Dec 19+ 1 more updateEXACT Therapeutics AS Announces Board AppointmentsEXACT Therapeutics AS welcomed two new board members, Vice Chair Jonathan Allis and Director Flavien Daloz, following the extraordinary general meeting on 17 December, 2024. In line with the development ambitions and internationalization of the Company over the last years and following the investment by GE Medical Holdings AB it has been the ambition to further internationalize the Board of Directors. The new board members, Jonathan Allis and Flavien Daloz, both bring significant industry experience. Dr. Jonathan Allis is a scientist turned entrepreneur and was the founding CEO of Blue Earth Diagnostics, a spin-out from GE Healthcare established in 2014. Blue Earth Diagnostics developed a prostate cancer diagnostic approved by the FDA in 2016, which became a successful product in the USA. The company was acquired by Bracco Imaging in 2019. Jonathan also served as a Board member and Chair of Polarean Imaging. Prior to these roles, Jonathan was the general manager for PET at GE Healthcare Life Sciences and was responsible for GE Healthcare’s PET agent and PET synthesis platforms business globally. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc., Siemens Medical Solutions and Oxford Magnet Technology in the UK, USA and Germany. Jonathan has an undergraduate degree in Physics from the University of Cape Town and a doctorate in Biochemistry from the University of Oxford. Mr. Flavien Daloz is the Chief Technology Officer for Ultrasound Probes under the GEHC Advanced Visualization Solutions segment. In his 15+ years of experience, Mr. Daloz has held various leadership positions in the Medical Ultrasound industry, with a proven record in innovation and new product introductions. He was the recipient of GEHC Edison Pioneer Award in 2021 for his influence in medical ultrasound transducer breakthrough. Mr. Daloz holds an engineering degree from ESPCI school in Paris and an MSc in Bioimaging sciences from Imperial College, London. He has completed a Business Leadership Program from Michigan Ross, US.New Risk • Dec 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr107.8m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (kr107.8m market cap, or US$9.63m).分析記事 • Aug 09Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Aug 07EXACT Therapeutics AS Announces Full Focus on Phase 2 Pancreatic Cancer TrialEXACT Therapeutics AS announced that it will now be focusing all clinical efforts on the upcoming Phase 2 ENACT trial in locally advanced pancreatic cancer and is stopping recruitment in the Phase 1 ACTIVATE clinical trial in cancer patients with liver metastases of colorectal origin. Previously, the Phase 1 ACTIVATE trial reported positive interim efficacy and safety data. The enrolled patients will be followed through the planned follow-up. The final results from the ACTIVATE Phase 1 trial (11 patients) will be reported after completion of independent blinded review, expected early 2025. So far, there has been no change to the previously reported excellent safety profile of PS101 in the ACTIVATE trial.New Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (kr4.5k revenue, or US$405). Minor Risks Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr255.0m market cap, or US$23.2m).分析記事 • Apr 20Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$42k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr192.5m market cap, or US$17.6m).New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Norwegian stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$43k). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr250.2m market cap, or US$23.5m).お知らせ • Jan 23+ 2 more updatesEXACT Therapeutics AS to Report Fiscal Year 2023 Results on Apr 18, 2024EXACT Therapeutics AS announced that they will report fiscal year 2023 results on Apr 18, 2024New Risk • Dec 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$44k). Minor Risks Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Significant insider selling over the past 3 months (kr650k sold). Market cap is less than US$100m (kr352.9m market cap, or US$34.5m).Recent Insider Transactions • Dec 05Chair of the Board recently sold kr300k worth of stockOn the 30th of November, Anders Wold sold around 25k shares on-market at roughly kr12.00 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anders has been a net seller over the last 12 months, reducing personal holdings by kr270k.お知らせ • Dec 02EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million.EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million. Security Name: Ordinarey Shares Security Type: Common Stock Securities Offered: 2,083,333 Price\Range: NOK 12 Transaction Features: Subsequent Direct Listingお知らせ • Sep 28EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023EXACT Therapeutics AS announced that Caspar Foghsgaard is joining the company as Senior Vice President Commercial and Business Development, effective 1 November 2023. Caspar Foghsgaard joins Exact Therapeutics from Nykode Therapeutics where his latest role was as Sr. Director Special Projects and part of the extended leadership team. He joined Nykode in 2018 and have been closely involved in Nykode’s transformation from a small biotech to a leading company at Oslo Stock Exchange. Prior to his role as Sr. Director Special Projects, he was heading Nykode’s business development activities as Director Business Development. Other previous employers include Arcus where he was responsible for business development in the spirits division and part of the divisional management, and Elopak as Program Director Strategy. In addition, he has held various business development and strategy positions including with Novozymes in Denmark, U.S. and U.K.お知らせ • Sep 27EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose EscalationEXACT THERAPEUTICS AS announced positive safety and anticancer activity results from the dose escalation part of the ACTIVATE trial. The data will be presented at a medical conference in early 2024. Eight patients were enrolled into the dose escalation part of the study. The results suggest that ACT treatment in combination with FOLFOX or FOLFIRI is well tolerated without unexpected acute or delayed side effects of the ACT treatment or worsening of side effects of the chemotherapy. Positive anticancer responses have been seen in all but one of the evaluable patients in this hard-to-treat patient population, showing that the ACT treatment can enhance anticancer response to Standard of Care chemotherapy.分析記事 • Sep 07We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...お知らせ • Aug 08EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE StudyEXACT Therapeutics AS announced that the dose escalation part of the ACTIVATE study is completed. This part of the study enrolled 8 patients, with 6 patients eligible for evaluation. The study is conducted at the Institute of Cancer Research (ICR), Royal Marsden Hospital, London with Professor Udai Banerji as the principal investigator. A presentation of the safety and efficacy findings will be released when the full results are available. The study Trial Monitoring Committee reviewed the safety data from the dose escalation and approved initiation of the dose expansion part of the ACTIVate study. The dose expansion is designed to determine the dose level for further development of ACT and expand the safety and efficacy data with 12 to 20 patients with metastatic colorectal cancer. All necessary approvals have already been awarded by the UK MHRA, as reported on July 31, and enrolment will now commence.お知らせ • Aug 01EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE StudyEXACT THERAPEUTICS AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has awarded all necessary approvals to start the dose expansion part of the ACTIVATE study. This part of the ACTIVATE study is designed to determine the dose level for further development and expand the safety and efficacy data of ACT in patients with metastatic colorectal cancer. 12 to 20 patients are planned to be enrolled into the dose expansion part of the ACTIVATE study.Board Change • Jun 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 10EXACT Therapeutics AS Announces Management ChangesEXACT Therapeutics AS at its Annual General Meeting held on June 9, 2023, announced Jean-Michel Cosséry is not seeking re-election as board member. In accordance with the Nomination Committee's proposal, the following Nomination Committee composition was made: Leiv Askvig (Chair); Dag Strømme; Birgitte Gangmark Villmo and Svein Kvåle.分析記事 • May 06We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Board Change • Apr 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 03Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical TrialOn February 2, 2023, EXACT Therapeutics AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has approved reopening of the clinical phase I ACTIVATE trial. As communicated in a press release of 8 March 2022, EXACT-Tx received a request from the MHRA for an additional submission and approval of medical device documentation associated to the protocol amendment filed with the ACTIVATE phase I clinical trial. EXACT-Tx responded to the request and has now received MHRA’s approval on both the medical device documentation and the amended protocol. The approvals were made without objections. For EXACT-Tx, this mean that the ACTIVATE phase I trial will be reopened and additional patients will be recruited for the trial. So far, there have been seven patients enrolled in the study with five patients’ data being evaluable for the study endpoints. Several valuable and encouraging insights have been gained from this first cohort of treated patients.Board Change • Jan 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 14+ 2 more updatesEXACT Therapeutics AS, Annual General Meeting, Jun 09, 2023EXACT Therapeutics AS, Annual General Meeting, Jun 09, 2023.分析記事 • Dec 30Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Board Change • Dec 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Sep 15Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Board Change • Sep 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jun 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Jan 31EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Recent Insider Transactions • Dec 07Executive Chairperson recently bought kr71k worth of stockOn the 3rd of December, Masha P. Strømme bought around 4k shares on-market at roughly kr16.59 per share. This was the largest purchase by an insider in the last 3 months. Masha P. has been a buyer over the last 12 months, purchasing a net total of kr206k worth in shares.Executive Departure • Dec 06Director Hans Klouman has left the companyOn the 3rd of December, Hans Klouman's tenure as Director ended. As of September 2021, Hans still personally held 399.75k shares (kr8.3m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.分析記事 • Aug 21We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Recent Insider Transactions • Jun 08Deputy Chairperson recently bought kr208k worth of stockOn the 4th of June, William Castell bought around 10k shares on-market at roughly kr20.80 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months.分析記事 • May 21We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...Executive Departure • Feb 03Chief Financial Officer has left the companyOn the 31st of January, Stig Pettersen's tenure in the role of Chief Financial Officer ended. As of September 2020, Stig personally held 30.00k shares (kr1.0m worth at the time). Stig is the only executive to leave the company over the last 12 months.お知らせ • Jan 31EXACT Therapeutics AS Announces Executive ChangesEXACT THERAPEUTICS AS announced that the company’s CFO Stig Jarle Pettersen, engaged as a part time consultant via his company CFO For Hire AS, will leave the company on January 31st 2021 at the end of his contracted period. The process of hiring a full time CFO is ongoing and Ole Fegth of Abaci AS will assume CFO responsibilities for the company until ad interim.お知らせ • Jan 22Exact Therapeutics Announces Innovative Probe Development Collaboration with GE HealthcareEXACT THERAPEUTICS AS announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across multiple disease conditions. ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as controlled blood-brain barrier opening. Currently ACT® is being evaluated in the international ACTIVATE Phase I clinical trial in patients with metastatic colorectal and pancreatic cancer at the Royal Marsden Hospital in London.Is New 90 Day High Low • Dec 03New 90-day low: kr25.50The company is down 29% from its price of kr36.00 on 04 September 2020. The Norwegian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 27% over the same period.Is New 90 Day High Low • Oct 15New 90-day low: kr31.50The company is down 7.0% from its price of kr34.02 on 17 July 2020. The Norwegian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 39% over the same period.お知らせ • Sep 09EXACT Therapeutics AS has completed an IPO in the amount of NOK 155.010604 million.EXACT Therapeutics AS has completed an IPO in the amount of NOK 155.010604 million. Security Name: Shares Security Type: Common Stock Securities Offered: 29,804 Price\Range: NOK 5201 Transaction Features: Direct Listing; Sponsor Backed Offeringお知らせ • Aug 23EXACT Therapeutics AS to Report Fiscal Year 2019 Results on Apr 29, 2021EXACT Therapeutics AS announced that they will report fiscal year 2019 results on Apr 29, 2021 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、EXACT Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OB:EXTX - アナリストの将来予測と過去の財務データ ( )NOK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-87-72-67N/A9/30/20250-80-80-75N/A6/30/2025N/A-72-89-84N/A3/31/2025N/A-62-85-82N/A12/31/2024N/A-52-82-81N/A9/30/2024N/A-54-65-63N/A6/30/2024N/A-55-48-45N/A3/31/20240-52-48-45N/A12/31/20230-48-47-44N/A9/30/20230-42-44-42N/A6/30/20230-36-40-39N/A3/31/20230-38-37-37N/A12/31/20220-40-34-34N/A9/30/20220-45-42-41N/A6/30/20220-49-49-49N/A3/31/20220-54-53-52N/A12/31/20210-59-57-55N/A9/30/20210-58-54-50N/A6/30/2021N/A-58-50-46N/A3/31/2021N/A-46-40-36N/A12/31/2020N/A-33-30-26N/A12/31/20190-15-14-12N/A12/31/20186-8N/AN/AN/A12/31/20178-5N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: EXTXの予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: EXTXの収益がNorwegian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: EXTXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: EXTXの収益がNorwegian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: EXTXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: EXTXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 10:26終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EXACT Therapeutics AS 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Apr 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.8m (US$9.64m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr72m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Revenue is less than US$1m (kr59k revenue, or US$6.3k). Market cap is less than US$10m (kr89.8m market cap, or US$9.64m).
お知らせ • Feb 13EXACT Therapeutics AS, Annual General Meeting, Jun 12, 2026EXACT Therapeutics AS, Annual General Meeting, Jun 12, 2026.
お知らせ • Feb 12+ 1 more updateEXACT Therapeutics AS to Report First Half, 2026 Results on Sep 03, 2026EXACT Therapeutics AS announced that they will report first half, 2026 results on Sep 03, 2026
New Risk • Jul 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr82m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr174.6m market cap, or US$17.2m).
お知らせ • Jun 24EXACT Therapeutics Announces First Patient Dosed in Phase 2 Trial in Patients with Locally Advanced Pancreatic CancerEXACT Therapeutics announced first patient dosed in its ENACT trial. The trial is a multi-centre, open-label Phase 2 clinical trial testing the safety and efficacy of Acoustic Cluster Therapy (ACT®) in combination with standard of care (modified FOLFIRINOX chemotherapy) in first line patients with borderline resectable or unresectable locally advanced pancreatic cancer. Dosing of the first patient in the Phase 2 trial follows the announcement of positive final efficacy and safety data in the Phase 1 trial in patients with liver metastases of colorectal origin. The Phase 2 trial will enroll up to 25 patients in the U.S., U.K. and Europe, and has the ClinicalTrials.gov Identification: NCT06850623.
お知らせ • Jun 13Exact Therapeutics AS Approves Election of Following Nomination Committee CompositionEXACT Therapeutics AS at its AGM held on June 13, 2025 approved to elect the following Nomination Committee composition: Svein Kvåle (Chair), Birgitte Gangmark Villmo, Sir William Castell.
お知らせ • May 20EXACT Therapeutics Announces Positive Final Results in Phase 1 ACTIVATE Trial in Liver Metastases from Colorectal CancerEXACT Therapeutics AS announced positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer. These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy (ACT®?) significantly enhances the local effect of chemotherapy; In the patients who had a response to chemotherapy, ACT-treated tumours showed a significantly greater reduction in diameter compared to control tumours (-29% vs. -7%, p. The final results affirm the previously reported positive ACTIVATE outcomes and indicate the significant added efficacy of ACT with chemotherapy compared with chemotherapy alone. Among patients who responded to chemotherapy, tumor shrinkage was significantly greater with ACT and chemotherapy compared to chemotherapy alone in the same individuals (29% vs. 7%, p<0.05).
New Risk • Jan 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 97% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr221.4m market cap, or US$19.6m).
お知らせ • Jan 29Cordance Medical and EXACT Therapeutics Announces Early Encouraging Data in Brain Cancer Mice ModelCordance Medical and EXACT Therapeutics announced initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics' proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and University Hospital North-Norway in Tromsø by Dr. Mathias Kranz. The combination of ACT® and the device can be used in a wide range of brain diseases to potentially access large regions of the brain. The combination can stimulate bioeffects including increasing the uptake of therapeutic agents and temporarily making the blood-brain barrier more permeable in these regions. The combination of ACT® and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals.
お知らせ • Jan 28Exact Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice ModelEXACT Therapeutics and Cordance Medical announced initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers. The increased uptake resulted from combining Exact Therapeutics’ proprietary Acoustic Cluster Therapy (ACT®) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and the University Hospital of North-Norway in Tromsø by Dr. Mathias Kranz. The combination of ACT and the device may offer potential applications across a wide range of brain diseases, by enabling therapeutic access to large brain regions. The combined technologies can induce bioeffects, such as temporarily increasing blood-brain barrier permeability in targeted regions and increasing the uptake of therapeutic agents. ACT and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals.
お知らせ • Jan 08EXACT Therapeutics AS, Annual General Meeting, Jun 13, 2025EXACT Therapeutics AS, Annual General Meeting, Jun 13, 2025.
お知らせ • Jan 07+ 1 more updateEXACT Therapeutics AS to Report Fiscal Year 2025 Results on Apr 09, 2025EXACT Therapeutics AS announced that they will report fiscal year 2025 results on Apr 09, 2025
お知らせ • Dec 19+ 1 more updateEXACT Therapeutics AS Announces Board AppointmentsEXACT Therapeutics AS welcomed two new board members, Vice Chair Jonathan Allis and Director Flavien Daloz, following the extraordinary general meeting on 17 December, 2024. In line with the development ambitions and internationalization of the Company over the last years and following the investment by GE Medical Holdings AB it has been the ambition to further internationalize the Board of Directors. The new board members, Jonathan Allis and Flavien Daloz, both bring significant industry experience. Dr. Jonathan Allis is a scientist turned entrepreneur and was the founding CEO of Blue Earth Diagnostics, a spin-out from GE Healthcare established in 2014. Blue Earth Diagnostics developed a prostate cancer diagnostic approved by the FDA in 2016, which became a successful product in the USA. The company was acquired by Bracco Imaging in 2019. Jonathan also served as a Board member and Chair of Polarean Imaging. Prior to these roles, Jonathan was the general manager for PET at GE Healthcare Life Sciences and was responsible for GE Healthcare’s PET agent and PET synthesis platforms business globally. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc., Siemens Medical Solutions and Oxford Magnet Technology in the UK, USA and Germany. Jonathan has an undergraduate degree in Physics from the University of Cape Town and a doctorate in Biochemistry from the University of Oxford. Mr. Flavien Daloz is the Chief Technology Officer for Ultrasound Probes under the GEHC Advanced Visualization Solutions segment. In his 15+ years of experience, Mr. Daloz has held various leadership positions in the Medical Ultrasound industry, with a proven record in innovation and new product introductions. He was the recipient of GEHC Edison Pioneer Award in 2021 for his influence in medical ultrasound transducer breakthrough. Mr. Daloz holds an engineering degree from ESPCI school in Paris and an MSc in Bioimaging sciences from Imperial College, London. He has completed a Business Leadership Program from Michigan Ross, US.
New Risk • Dec 17New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr107.8m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (kr107.8m market cap, or US$9.63m).
分析記事 • Aug 09Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Aug 07EXACT Therapeutics AS Announces Full Focus on Phase 2 Pancreatic Cancer TrialEXACT Therapeutics AS announced that it will now be focusing all clinical efforts on the upcoming Phase 2 ENACT trial in locally advanced pancreatic cancer and is stopping recruitment in the Phase 1 ACTIVATE clinical trial in cancer patients with liver metastases of colorectal origin. Previously, the Phase 1 ACTIVATE trial reported positive interim efficacy and safety data. The enrolled patients will be followed through the planned follow-up. The final results from the ACTIVATE Phase 1 trial (11 patients) will be reported after completion of independent blinded review, expected early 2025. So far, there has been no change to the previously reported excellent safety profile of PS101 in the ACTIVATE trial.
New Risk • Jul 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (kr4.5k revenue, or US$405). Minor Risks Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr255.0m market cap, or US$23.2m).
分析記事 • Apr 20Is EXACT Therapeutics (OB:EXTX) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$42k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr192.5m market cap, or US$17.6m).
New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Norwegian stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$43k). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (kr250.2m market cap, or US$23.5m).
お知らせ • Jan 23+ 2 more updatesEXACT Therapeutics AS to Report Fiscal Year 2023 Results on Apr 18, 2024EXACT Therapeutics AS announced that they will report fiscal year 2023 results on Apr 18, 2024
New Risk • Dec 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr453k revenue, or US$44k). Minor Risks Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Significant insider selling over the past 3 months (kr650k sold). Market cap is less than US$100m (kr352.9m market cap, or US$34.5m).
Recent Insider Transactions • Dec 05Chair of the Board recently sold kr300k worth of stockOn the 30th of November, Anders Wold sold around 25k shares on-market at roughly kr12.00 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anders has been a net seller over the last 12 months, reducing personal holdings by kr270k.
お知らせ • Dec 02EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million.EXACT Therapeutics AS has completed a Follow-on Equity Offering in the amount of NOK 24.999996 million. Security Name: Ordinarey Shares Security Type: Common Stock Securities Offered: 2,083,333 Price\Range: NOK 12 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 28EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023EXACT Therapeutics AS announced that Caspar Foghsgaard is joining the company as Senior Vice President Commercial and Business Development, effective 1 November 2023. Caspar Foghsgaard joins Exact Therapeutics from Nykode Therapeutics where his latest role was as Sr. Director Special Projects and part of the extended leadership team. He joined Nykode in 2018 and have been closely involved in Nykode’s transformation from a small biotech to a leading company at Oslo Stock Exchange. Prior to his role as Sr. Director Special Projects, he was heading Nykode’s business development activities as Director Business Development. Other previous employers include Arcus where he was responsible for business development in the spirits division and part of the divisional management, and Elopak as Program Director Strategy. In addition, he has held various business development and strategy positions including with Novozymes in Denmark, U.S. and U.K.
お知らせ • Sep 27EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose EscalationEXACT THERAPEUTICS AS announced positive safety and anticancer activity results from the dose escalation part of the ACTIVATE trial. The data will be presented at a medical conference in early 2024. Eight patients were enrolled into the dose escalation part of the study. The results suggest that ACT treatment in combination with FOLFOX or FOLFIRI is well tolerated without unexpected acute or delayed side effects of the ACT treatment or worsening of side effects of the chemotherapy. Positive anticancer responses have been seen in all but one of the evaluable patients in this hard-to-treat patient population, showing that the ACT treatment can enhance anticancer response to Standard of Care chemotherapy.
分析記事 • Sep 07We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
お知らせ • Aug 08EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE StudyEXACT Therapeutics AS announced that the dose escalation part of the ACTIVATE study is completed. This part of the study enrolled 8 patients, with 6 patients eligible for evaluation. The study is conducted at the Institute of Cancer Research (ICR), Royal Marsden Hospital, London with Professor Udai Banerji as the principal investigator. A presentation of the safety and efficacy findings will be released when the full results are available. The study Trial Monitoring Committee reviewed the safety data from the dose escalation and approved initiation of the dose expansion part of the ACTIVate study. The dose expansion is designed to determine the dose level for further development of ACT and expand the safety and efficacy data with 12 to 20 patients with metastatic colorectal cancer. All necessary approvals have already been awarded by the UK MHRA, as reported on July 31, and enrolment will now commence.
お知らせ • Aug 01EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE StudyEXACT THERAPEUTICS AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has awarded all necessary approvals to start the dose expansion part of the ACTIVATE study. This part of the ACTIVATE study is designed to determine the dose level for further development and expand the safety and efficacy data of ACT in patients with metastatic colorectal cancer. 12 to 20 patients are planned to be enrolled into the dose expansion part of the ACTIVATE study.
Board Change • Jun 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 10EXACT Therapeutics AS Announces Management ChangesEXACT Therapeutics AS at its Annual General Meeting held on June 9, 2023, announced Jean-Michel Cosséry is not seeking re-election as board member. In accordance with the Nomination Committee's proposal, the following Nomination Committee composition was made: Leiv Askvig (Chair); Dag Strømme; Birgitte Gangmark Villmo and Svein Kvåle.
分析記事 • May 06We're Hopeful That EXACT Therapeutics (OB:EXTX) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Board Change • Apr 21No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 03Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical TrialOn February 2, 2023, EXACT Therapeutics AS announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has approved reopening of the clinical phase I ACTIVATE trial. As communicated in a press release of 8 March 2022, EXACT-Tx received a request from the MHRA for an additional submission and approval of medical device documentation associated to the protocol amendment filed with the ACTIVATE phase I clinical trial. EXACT-Tx responded to the request and has now received MHRA’s approval on both the medical device documentation and the amended protocol. The approvals were made without objections. For EXACT-Tx, this mean that the ACTIVATE phase I trial will be reopened and additional patients will be recruited for the trial. So far, there have been seven patients enrolled in the study with five patients’ data being evaluable for the study endpoints. Several valuable and encouraging insights have been gained from this first cohort of treated patients.
Board Change • Jan 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 14+ 2 more updatesEXACT Therapeutics AS, Annual General Meeting, Jun 09, 2023EXACT Therapeutics AS, Annual General Meeting, Jun 09, 2023.
分析記事 • Dec 30Here's Why We're Watching EXACT Therapeutics' (OB:EXTX) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Board Change • Dec 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Sep 15Companies Like EXACT Therapeutics (OB:EXTX) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Board Change • Sep 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 22No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chair of the Board Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jun 08No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Anders Wold was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Jan 31EXACT Therapeutics (OB:EXTX) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Recent Insider Transactions • Dec 07Executive Chairperson recently bought kr71k worth of stockOn the 3rd of December, Masha P. Strømme bought around 4k shares on-market at roughly kr16.59 per share. This was the largest purchase by an insider in the last 3 months. Masha P. has been a buyer over the last 12 months, purchasing a net total of kr206k worth in shares.
Executive Departure • Dec 06Director Hans Klouman has left the companyOn the 3rd of December, Hans Klouman's tenure as Director ended. As of September 2021, Hans still personally held 399.75k shares (kr8.3m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
分析記事 • Aug 21We Think EXACT Therapeutics (OB:EXTX) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Recent Insider Transactions • Jun 08Deputy Chairperson recently bought kr208k worth of stockOn the 4th of June, William Castell bought around 10k shares on-market at roughly kr20.80 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months.
分析記事 • May 21We're Not Very Worried About EXACT Therapeutics' (OB:EXTX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Executive Departure • Feb 03Chief Financial Officer has left the companyOn the 31st of January, Stig Pettersen's tenure in the role of Chief Financial Officer ended. As of September 2020, Stig personally held 30.00k shares (kr1.0m worth at the time). Stig is the only executive to leave the company over the last 12 months.
お知らせ • Jan 31EXACT Therapeutics AS Announces Executive ChangesEXACT THERAPEUTICS AS announced that the company’s CFO Stig Jarle Pettersen, engaged as a part time consultant via his company CFO For Hire AS, will leave the company on January 31st 2021 at the end of his contracted period. The process of hiring a full time CFO is ongoing and Ole Fegth of Abaci AS will assume CFO responsibilities for the company until ad interim.
お知らせ • Jan 22Exact Therapeutics Announces Innovative Probe Development Collaboration with GE HealthcareEXACT THERAPEUTICS AS announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across multiple disease conditions. ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as controlled blood-brain barrier opening. Currently ACT® is being evaluated in the international ACTIVATE Phase I clinical trial in patients with metastatic colorectal and pancreatic cancer at the Royal Marsden Hospital in London.
Is New 90 Day High Low • Dec 03New 90-day low: kr25.50The company is down 29% from its price of kr36.00 on 04 September 2020. The Norwegian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 27% over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: kr31.50The company is down 7.0% from its price of kr34.02 on 17 July 2020. The Norwegian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 39% over the same period.
お知らせ • Sep 09EXACT Therapeutics AS has completed an IPO in the amount of NOK 155.010604 million.EXACT Therapeutics AS has completed an IPO in the amount of NOK 155.010604 million. Security Name: Shares Security Type: Common Stock Securities Offered: 29,804 Price\Range: NOK 5201 Transaction Features: Direct Listing; Sponsor Backed Offering
お知らせ • Aug 23EXACT Therapeutics AS to Report Fiscal Year 2019 Results on Apr 29, 2021EXACT Therapeutics AS announced that they will report fiscal year 2019 results on Apr 29, 2021